albumin-bound paclitaxel / Generic mfg. - LARVOL DELTA

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=117 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2025 ➔ Dec 2026 | Trial primary completion date: Sep 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • BRAF • EGFR • KRAS • PD-L1 • ROS1

PRECIOUS: A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=226 | Completed | Sponsor: Japan Breast Cancer Research Group | Unknown status ➔ Completed | N=370 ➔ 226

Enrollment change • Trial completion • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

BELLA: A Phase 2 Study of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (ESMO 2025) - No abstract available

Clinical • P2 data • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

A Prospective Interventional Study of Preoperative PD-1 Monoclonal Antibody (Toripalimab) Combined with Gemcitabine and Albumin-bound Paclitaxel for Borderline Resectable and Locally Advanced Pancreatic Cancer (ESMO 2025) - No abstract available

Clinical • Metastases • Oncology • Pancreatic Cancer • Solid Tumor

Phase Ib/II Clinical Study of Adebrelimab Combined with Decitabine, Nab-Paclitaxel, and Gemcitabine as First-Line (IL) Treatment for Metastatic Pancreatic Cancer (mPC) (ESMO 2025) - No abstract available

Clinical • Metastases • P1/2 data • Oncology • Pancreatic Cancer • Solid Tumor

Peripheral immunological responses to immunotherapy combined with gemcitabine, nab-paclitaxel, and adaptive stereotactic body radiotherapy in pancreatic cancer (LAPTOP) (ESMO 2025) - No abstract available

Oncology • Pancreatic Cancer • Solid Tumor

Real-World Efficacy and Safety of NALIRIFOX Versus Modified-FOLFIRINOX or Gemcitabine and nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma: A Propensity Score–Matched Cohort Study (ESMO 2025) - No abstract available

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer

Efficacy/safety and preliminary scRNA-seq results of surufatinib plus gemcitabine and nab-paclitaxel as neoadjuvant therapy in resectable and borderline resectable pancreatic cancer (ESMO 2025) - No abstract available

Clinical • Oncology • Pancreatic Cancer • Solid Tumor

The ALLEN regimen (Durvalumab plus Albumin-paclitaxel and Lenvatinib) for metastatic pancreatic cancer: A prospective, single-arm, Phase 2 study (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

A phase II study of Sitagliptin combined with gemcitabine and albumin-bound paclitaxel as a first-line treatment for subjects with locally advanced or metastatic pancreatic ductal adenocarcinoma (SITGEM-CARE) (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

First-line Serplulimab and Bevacizumab Combined with Nab-Paclitaxel/Gemcitabine Followed by mFOLFOX in Advanced Pancreatic Cancer: A Phase II Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

Safety and clinical efficacy of cambritaxestat (IOA-289), a novel autotaxin inhibitor, plus gemcitabine and nab-paclitaxel (GnP)in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC) (ESMO 2025) - No abstract available

Clinical • Metastases • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

High response rate of gemcitabine, nab-paclitaxel, and S-1 in patients with locally advanced or metastatic pancreatic cancer: results from a phase II GeNeS1S Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

Final results of FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC). (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

AGITG ASCEND: Randomised, Double-Blind Phase 2 Trial of Certepetide (CERT) or Placebo (PLA) with Gemcitabine (Gem) + Nab-Paclitaxel (Nab) in Patients with Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC): Updated Results Including Planned Pooled Placebo Analysis. (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

A prospective, open and single-arm phase II clinical study of Nab-Paclitaxel combined with cisplatin and PD-1 inhibitor followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Oncology

Cadonilimab in combination with disitamab vedotin or nab-paclitaxel in the treatment of recurrent or metastatic cervical cancer: A prospective, double-cohort, multi-center, open-label, phase II clinical study (AK001) (ESMO 2025) - No abstract available

Clinical • Combination therapy • Metastases • P2 data • Cervical Cancer • Oncology • Solid Tumor

Phase I Study of Tumor Treating Fields (TTFs) with Cabozantinib or with Nab-Paclitaxel and Pembrolizumab in Patients with Advanced Solid Tumors Involving the Abdomen or Thorax (ESMO 2025) - No abstract available

Clinical • Metastases • P1 data • Oncology • Solid Tumor

Randomized phase 2 study of paclitaxel plus bevacizumab induction followed by atezolizumab plus nab-paclitaxel in patients with PD-L1–positive metastatic triple-negative breast cancer with biomarker analysis (JBCRG-M10/INDUCE) (ESMO 2025) - No abstract available

Biomarker • Clinical • IO biomarker • Metastases • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • PD-L1

PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. (PubMed, J Clin Oncol) - "In the phase II Pancreatic Adenocarcinoma Signature Stratification for Treatment-01 (PASS-01) trial population, PFS was similar between GnP and mFFX; however, OS and safety trends favored GnP. The second-line setting appears inadequate to offer precision choices, given the short survival observed."

Journal • P2 data • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • BRCA1 • BRCA2 • PALB2

VIRAGE trial: randomized Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer (mPDAC) (ESMO 2025) - No abstract available

Clinical • Metastases • P2b data • Oncology • Pancreatic Cancer • Solid Tumor

HRS-4642 Combined with Gemcitabine and Nab-paclitaxel in KRAS-G12D Mutant Advanced Pancreatic Cancer: A Phase 1b/2 Study (ESMO 2025) - No abstract available

Metastases • P1/2 data • Oncology • Pancreatic Cancer • Solid Tumor • KRAS

A prospective, double-cohort, open-label, phase II clinical study of cadonilimab combined with nab-paclitaxel or disitamab vedotin in the treatment of recurrent or metastatic cervical cancer (ChiCTR) - P2 | N=74 | Recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center | Not yet recruiting ➔ Recruiting

Enrollment open • Cervical Cancer • Oncology • Solid Tumor • HER-2

Evaluating cadonilimab efficacy and safety in retrospective first line treatment for advanced pancreatic cancer. (PubMed, iScience) - "Patients received either gemcitabine with nab-paclitaxel or the same chemotherapy combined with cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4...The safety profile of the combination regimen was manageable, with treatment-related adverse events comparable between groups. These findings provide evidence that integrating cadonilimab into standard chemotherapy may enhance treatment outcomes in advanced PDAC, highlighting a potential therapeutic strategy that merits further evaluation in prospective studies."

Journal • Retrospective data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

A Phase I/II Study of CS2009 as Monotherapy and Combination Therapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=660 | Recruiting | Sponsor: CStone Pharmaceuticals | Phase classification: P1 ➔ P1/2 | N=230 ➔ 660

Enrollment change • Monotherapy • Phase classification • Oncology • Solid Tumor